Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07437950CT.gov Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | — | Not Yet Recruiting | — | — | — |
NCT07617363CT.gov ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | — | Not Yet Recruiting | — | — | — |
NCT07511062CT.gov Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | — | Not Yet Recruiting | — | — | — |
NCT07012044CT.gov A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT07153497CT.gov Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | — | Not Yet Recruiting | — | — | — |
NCT06802523CT.gov Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT07060001CT.gov Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | — | Not Yet Recruiting | — | — | — |
NCT07507760CT.gov Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | — | Not Yet Recruiting | — | — | — |
NCT07177079CT.gov High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT07505160CT.gov Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients | — | Not Yet Recruiting | — | — | — |
Show 162 more trialsShow fewer
NCT07374029CT.gov Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | — | Recruiting | — | — | — |
NCT07283094CT.gov FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06928662CT.gov Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | — | Recruiting | — | — | — |
NCT07451912CT.gov Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | — | Recruiting | — | — | — |
NCT06484062CT.gov Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | — | Recruiting | — | — | — |
NCT06129734CT.gov Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | — | Recruiting | — | — | — |
NCT07044544CT.gov Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | — | Recruiting | — | — | — |
NCT06972641CT.gov Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT06572631CT.gov Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor | — | Withdrawn | — | — | — |
NCT06672146CT.gov Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT05766514CT.gov Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | — | Withdrawn | — | — | — |
NCT06778187CT.gov Oral-ATO for TP53-mutated Myeloid Malignancies | — | Recruiting | — | — | — |
NCT07117422CT.gov Venetoclax-Decitabine in Untreated Elderly/Unfit AML | — | Recruiting | — | — | — |
NCT06511882CT.gov Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | — | Recruiting | — | — | — |
NCT06741722CT.gov Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | — | Recruiting | — | — | — |
NCT07163793CT.gov Pilot Study of Reduced Venetoclax Exposure | — | Recruiting | — | — | — |
NCT06337331CT.gov Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | — | Withdrawn | — | — | — |
NCT06536959CT.gov VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | — | Recruiting | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT06351306CT.gov DEC-C and Thioguanine for R/R AML | — | Withdrawn | — | — | — |
NCT06316960CT.gov Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | — | Recruiting | — | — | — |
NCT06499025CT.gov Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) | — | Enrolling By Invitation | — | — | — |
NCT06429098CT.gov Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | — | Recruiting | — | — | — |
NCT05883956CT.gov A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT06156579CT.gov Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML | — | Recruiting | — | — | — |
NCT06046313CT.gov Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | — | Recruiting | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05799079CT.gov Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | — | Terminated | — | — | — |
NCT05586074CT.gov HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | — | Recruiting | — | — | — |
NCT05636514CT.gov Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | — | Recruiting | — | — | — |
NCT05829226CT.gov A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT05603884CT.gov VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05396859CT.gov Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05190471CT.gov A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05222984CT.gov Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | — | Active Not Recruiting | — | — | — |
NCT05456269CT.gov A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | — | Withdrawn | — | — | — |
NCT05455294CT.gov Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT06827899CT.gov Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | — | Recruiting | — | — | — |
NCT04655391CT.gov Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | — | Withdrawn | — | — | — |
NCT05362942CT.gov Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05184842CT.gov Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | — | Recruiting | — | — | — |
NCT05177731CT.gov Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | — | Active Not Recruiting | — | — | — |
NCT04817241CT.gov Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | — | Active Not Recruiting | — | — | — |
NCT04905810CT.gov Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | — | Recruiting | — | — | — |
NCT04763928CT.gov Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax | — | Active Not Recruiting | — | — | — |
NCT05010772CT.gov Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | — | Recruiting | — | — | — |
NCT04975919CT.gov Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05010122CT.gov ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT04891757CT.gov FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT04774393CT.gov Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05264883CT.gov Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | — | Unknown | — | — | — |
NCT04746235CT.gov Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04657081CT.gov Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | — | Active Not Recruiting | — | — | — |
NCT04229979CT.gov Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | — | Active Not Recruiting | — | — | — |
NCT06379360CT.gov Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | — | Recruiting | — | — | — |
NCT04146038CT.gov Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | — | Completed | — | — | — |
NCT04493099CT.gov Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | — | Withdrawn | — | — | — |
NCT04485052CT.gov Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT04188405CT.gov Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT03969446CT.gov Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | — | Recruiting | — | — | — |
NCT04353479CT.gov Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT04282187CT.gov Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | — | Recruiting | — | — | — |
NCT04277442CT.gov Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT04055844CT.gov Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | — | Completed | — | — | — |
NCT04476199CT.gov Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | — | Active Not Recruiting | — | — | — |
NCT04051996CT.gov GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03926624CT.gov Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | — | Terminated | — | — | — |
NCT03844815CT.gov Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04113616CT.gov An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT04013880CT.gov ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT03941964CT.gov A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT04083911CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | — | Unknown | — | — | — |
NCT04087967CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | — | Unknown | — | — | — |
NCT03752138CT.gov TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT05456048CT.gov Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML | — | Completed | — | — | — |
NCT03813186CT.gov Effect of Food on Blood Levels of ASTX727 | — | Completed | — | — | — |
NCT03661307CT.gov Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT03613532CT.gov Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | — | Active Not Recruiting | — | — | — |
NCT03793517CT.gov Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT | — | Recruiting | — | — | — |
NCT03358719CT.gov DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03381781CT.gov Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | — | Unknown | — | — | — |
NCT03306264CT.gov Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | — | Completed | — | — | — |
NCT03041688CT.gov Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03092674CT.gov Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03404193CT.gov Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT03855371CT.gov Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | — | Unknown | — | — | — |
NCT03985007CT.gov CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03303339CT.gov Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02890329CT.gov Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03256071CT.gov Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | — | Unknown | — | — | — |
NCT03009240CT.gov Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03132454CT.gov Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | — | Active Not Recruiting | — | — | — |
NCT03263936CT.gov Epigenetic Reprogramming in Relapse/Refractory AML | — | Completed | — | — | — |
NCT03356080CT.gov DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | — | Unknown | — | — | — |
NCT03066648CT.gov Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03113071CT.gov Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | — | Terminated | — | — | — |
NCT03146871CT.gov Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | — | Terminated | — | — | — |
NCT03063944CT.gov STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT02996474CT.gov Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02954653CT.gov A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02921061CT.gov Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | — | Completed | — | — | — |
NCT03013998CT.gov Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT02937662CT.gov Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | — | Completed | — | — | — |
NCT02878785CT.gov Decitabine and Talazoparib in Untreated AML and R/R AML | — | Completed | — | — | — |
NCT02632721CT.gov A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02886559CT.gov Chidamide Plus DCAG for Relapsed/Refractory AML | — | Unknown | — | — | — |
NCT02785900CT.gov Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02781883CT.gov Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | — | Recruiting | — | — | — |
NCT02323607CT.gov Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | — | Completed | — | — | — |
NCT02634827CT.gov Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | — | Terminated | — | — | — |
NCT02472145CT.gov An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT02343939CT.gov Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02532010CT.gov Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | — | Terminated | — | — | — |
NCT02073838CT.gov Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | — | Completed | — | — | — |
NCT02316964CT.gov Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02662647CT.gov Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML | — | Completed | — | — | — |
NCT02348489CT.gov SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | — | Completed | — | — | — |
NCT02412475CT.gov Epigenetic Reprogramming in Relapse AML | — | Terminated | — | — | — |
NCT02257138CT.gov Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02272478CT.gov Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | — | Unknown | — | — | — |
NCT02488408CT.gov A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | — | Completed | — | — | — |
NCT02203773CT.gov Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT02204085CT.gov A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02129101CT.gov Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | — | Completed | — | — | — |
NCT02093403CT.gov Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02072811CT.gov Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02003573CT.gov Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT01853228CT.gov A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01798901CT.gov AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01834248CT.gov DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01861314CT.gov Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT01846624CT.gov Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02190695CT.gov Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | — | Completed | — | — | — |
NCT01829503CT.gov Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01729845CT.gov Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01758367CT.gov Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | — | Unknown | — | — | — |
NCT02084563CT.gov Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | — | Completed | — | — | — |
NCT01607645CT.gov Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | — | Terminated | — | — | — |
NCT01546038CT.gov A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01303796CT.gov A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00867672CT.gov Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01352650CT.gov Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01211457CT.gov Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | — | Unknown | — | — | — |
NCT00943553CT.gov A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | — | Withdrawn | — | — | — |
NCT01130506CT.gov Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01001143CT.gov Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT01130662CT.gov Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00861874CT.gov A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01041443CT.gov 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01455506CT.gov PRO#0118: Decitabine Plus Mini Flu-Bu | — | Completed | — | — | — |
NCT00882102CT.gov Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | — | Completed | — | — | — |
NCT00778375CT.gov Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT00691938CT.gov LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00671697CT.gov Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00968071CT.gov Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00479232CT.gov Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | — | Completed | — | — | — |
NCT00414310CT.gov Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT00357708CT.gov Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | — | Completed | — | — | — |
NCT00275080CT.gov Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | — | Completed | — | — | — |
NCT00079378CT.gov Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Completed | — | — | — |
NCT00866073CT.gov Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | National Cancer Institute (NCI) | Approved | BB · 67 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-acute-myeloid-leukemia-2753
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →